Copyright
©The Author(s) 2020.
World J Crit Care Med. Jan 31, 2020; 9(1): 1-12
Published online Jan 31, 2020. doi: 10.5492/wjccm.v9.i1.1
Published online Jan 31, 2020. doi: 10.5492/wjccm.v9.i1.1
Table 1 Baseline characteristics of all the patients, survivors and non-survivors before initiating the therapy (mean ± SD)
Baseline characteristics | Survivors (n = 40) | Non-survivors (n = 60) | P value (survivors vs non-survivors) |
Age (yr) | 51.3 ± 16.66 | 53.66 ± 16.47 | 0.4864 |
Urine output (mL/d) | 551.13 ± 524.60 | 666.48 ± 595.25 | 0.3224 |
MAP (mmHg) | 62.82 ± 9.73 | 66.31 ± 9.48 | 0.0774 |
GCS | 6.26 ± 3.67 | 6.12 ± 4.56 | 0.8715 |
APACHE-II | 24.6 ± 7.32 | 27.61 ± 9.29 | 0.0881 |
SOFA | 12.3 ± 3.17 | 15.05 ± 3.35 | 0.0001 |
Leucocytes (cells/mm3) | 15.60 ± 8.56 | 21.40 ± 26.17 | 0.1794 |
Platelets (cells/mm3) | 123.95 ± 51.42 | 110.53 ± 50.18 | 0.1976 |
BUN | 58.45 ± 36.94 | 108.55 ± 92.10 | 0.0015 |
SGOT(U/L) | 1135.74 ± 2206.67 | 616.25 ± 1353.71 | 0.1477 |
SGPT(U/L) | 504.63 ± 876.89 | 540.93 ± 1216.70 | 0.8712 |
S. Creatinine (mg/dL) | 2.73 ± 1.86 | 7.01 ± 23.41 | 0.2521 |
S. Lactate (mg/dL) | 3.71 ± 2.30 | 4.18 ± 3.23 | 0.3812 |
PaCO2 | 38.46 ± 14.51 | 40.89 ± 12.20 | 0.3682 |
PaO2 | 96.78 ± 41.42 | 84.50 ± 48.56 | 0.1920 |
FiO2 | 49.32 ± 18.71 | 69.15 ± 67.74 | 0.0744 |
- Citation: Mehta Y, Mehta C, Kumar A, George JV, Gupta A, Nanda S, Kochhar G, Raizada A. Experience with hemoadsorption (CytoSorb®) in the management of septic shock patients. World J Crit Care Med 2020; 9(1): 1-12
- URL: https://www.wjgnet.com/2220-3141/full/v9/i1/1.htm
- DOI: https://dx.doi.org/10.5492/wjccm.v9.i1.1